Cargando…

HER2-Specific Pseudomonas Exotoxin A PE25 Based Fusions: Influence of Targeting Domain on Target Binding, Toxicity, and In Vivo Biodistribution

The human epidermal growth factor receptor 2 (HER2) is a clinically validated target for cancer therapy, and targeted therapies are often used in regimens for patients with a high HER2 expression level. Despite the success of current drugs, a number of patients succumb to their disease, which motiva...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ding, Haozhong, Altai, Mohamed, Yin, Wen, Lindbo, Sarah, Liu, Hao, Garousi, Javad, Xu, Tianqi, Orlova, Anna, Tolmachev, Vladimir, Hober, Sophia, Gräslund, Torbjörn
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7238247/ https://www.ncbi.nlm.nih.gov/pubmed/32344762 http://dx.doi.org/10.3390/pharmaceutics12040391

Ejemplares similares

Targeting HER2 Expressing Tumors with a Potent Drug Conjugate Based on an Albumin Binding Domain-Derived Affinity Protein
por: Garousi, Javad, et al.
Publicado: (2021)

Affibody-Derived Drug Conjugates Targeting HER2: Effect of Drug Load on Cytotoxicity and Biodistribution
por: Ding, Haozhong, et al.
Publicado: (2021)

Experimental HER2-Targeted Therapy Using ADAPT6-ABD-mcDM1 in Mice Bearing SKOV3 Ovarian Cancer Xenografts: Efficacy and Selection of Companion Imaging Counterpart
por: Garousi, Javad, et al.
Publicado: (2022)

Incorporation of a Hydrophilic Spacer Reduces Hepatic Uptake of HER2-Targeting Affibody–DM1 Drug Conjugates
por: Ding, Haozhong, et al.
Publicado: (2019)

Comparative evaluation of tumor targeting using the anti-HER2 ADAPT scaffold protein labeled at the C-terminus with indium-111 or technetium-99m
por: Garousi, Javad, et al.
Publicado: (2017)

Drug Conjugates Based on a Monovalent Affibody Targeting Vector Can Efficiently Eradicate HER2 Positive Human Tumors in an Experimental Mouse Model
por: Xu, Tianqi, et al.
Publicado: (2020)

Effect of Inter-Domain Linker Composition on Biodistribution of ABD-Fused Affibody-Drug Conjugates Targeting HER2
por: Xu, Tianqi, et al.
Publicado: (2022)

The Influence of Domain Permutations of an Albumin-Binding Domain-Fused HER2-Targeting Affibody-Based Drug Conjugate on Tumor Cell Proliferation and Therapy Efficacy
por: Yin, Wen, et al.
Publicado: (2021)

Imaging-Guided Therapy Simultaneously Targeting HER2 and EpCAM with Trastuzumab and EpCAM-Directed Toxin Provides Additive Effect in Ovarian Cancer Model
por: Xu, Tianqi, et al.
Publicado: (2021)

Influence of composition of cysteine-containing peptide-based chelators on biodistribution of (99m)Tc-labeled anti-EGFR affibody molecules
por: Oroujeni, Maryam, et al.
Publicado: (2018)

Influence of the Position and Composition of Radiometals and Radioiodine Labels on Imaging of Epcam Expression in Prostate Cancer Model Using the DARPin Ec1
por: Deyev, Sergey M., et al.
Publicado: (2021)

Investigation of a Pharmacological Approach for Reduction of Renal Uptake of Radiolabeled ADAPT Scaffold Protein
por: Vorobyeva, Anzhelika, et al.
Publicado: (2020)

Imaging using radiolabelled targeted proteins: radioimmunodetection and beyond
por: Garousi, Javad, et al.
Publicado: (2020)

Feasibility of Imaging EpCAM Expression in Ovarian Cancer Using Radiolabeled DARPin Ec1
por: Vorobyeva, Anzhelika, et al.
Publicado: (2020)

Evaluation of (99m)Tc-Z(IGF1R:4551)-GGGC affibody molecule, a new probe for imaging of insulin-like growth factor type 1 receptor expression
por: Mitran, Bogdan, et al.
Publicado: (2014)

Site-Specific Radioiodination of HER2-Targeting Affibody Molecules using 4-Iodophenethylmaleimide Decreases Renal Uptake of Radioactivity
por: Strand, Joanna, et al.
Publicado: (2015)

Direct In Vivo Comparison of (99m)Tc-Labeled Scaffold Proteins, DARPin G3 and ADAPT6, for Visualization of HER2 Expression and Monitoring of Early Response for Trastuzumab Therapy
por: Tolmachev, Vladimir, et al.
Publicado: (2022)

Molecular Design of HER3-Targeting Affibody Molecules: Influence of Chelator and Presence of HEHEHE-Tag on Biodistribution of (68)Ga-Labeled Tracers
por: Dahlsson Leitao, Charles, et al.
Publicado: (2019)

Influence of Molecular Design on the Targeting Properties of ABD-Fused Mono- and Bi-Valent Anti-HER3 Affibody Therapeutic Constructs
por: Altai, Mohamed, et al.
Publicado: (2018)

Comparison of tumor-targeting properties of directly and indirectly radioiodinated designed ankyrin repeat protein (DARPin) G3 variants for molecular imaging of HER2
por: Vorobyeva, Anzhelika, et al.
Publicado: (2019)

Optimal composition and position of histidine-containing tags improves biodistribution of (99m)Tc-labeled DARPin G3
por: Vorobyeva, Anzhelika, et al.
Publicado: (2019)

Evaluating the Therapeutic Efficacy of Mono- and Bivalent Affibody-Based Fusion Proteins Targeting HER3 in a Pancreatic Cancer Xenograft Model
por: Dahlsson Leitao, Charles, et al.
Publicado: (2020)

Comparative Preclinical Evaluation of Peptide-Based Chelators for the Labeling of DARPin G3 with (99m)Tc for Radionuclide Imaging of HER2 Expression in Cancer
por: Larkina, Mariia, et al.
Publicado: (2022)

Inactivated Pseudomonas PE(ΔIII) exotoxin fused to neutralizing epitopes of PEDV S proteins produces a specific immune response in mice
por: Sun, Leqiang, et al.
Publicado: (2021)

A chemical conjugate between HER2-targeting antibody fragment and Pseudomonas exotoxin A fragment demonstrates cytotoxic effects on HER2-expressing breast cancer cells
por: Lee, Sunju, et al.
Publicado: (2019)

Therapeutic Efficacy of Cintredekin Besudotox (IL13-PE38QQR) in Murine Lung Fibrosis Is Unaffected by Immunity to Pseudomonas aeruginosa Exotoxin A
por: Rosada, Rogério S., et al.
Publicado: (2010)

Pseudomonas Exotoxin-Based Immunotoxins: Over Three Decades of Efforts on Targeting Cancer Cells With the Toxin
por: Havaei, Seyed Mehdi, et al.
Publicado: (2021)

(177)Lu-labeled PSMA targeting therapeutic with optimized linker for treatment of disseminated prostate cancer; evaluation of biodistribution and dosimetry
por: Abouzayed, Ayman, et al.
Publicado: (2023)

Experimental Therapy of HER2-Expressing Xenografts Using the Second-Generation HER2-Targeting Affibody Molecule (188)Re-ZHER2:41071
por: Liu, Yongsheng, et al.
Publicado: (2022)

Exotoxin-Targeted Drug Modalities as Antibiotic Alternatives
por: Sakari, Moona, et al.
Publicado: (2022)

Influence of Several Compounds and Drugs on the Renal Uptake of Radiolabeled Affibody Molecules
por: Garousi, Javad, et al.
Publicado: (2020)

Preclinical Evaluation of a New Format of (68)Ga- and (111)In-Labeled Affibody Molecule Z(IGF-1R:4551) for the Visualization of IGF-1R Expression in Malignant Tumors Using PET and SPECT
por: Liu, Yongsheng, et al.
Publicado: (2022)

Pseudomonas Exotoxin A: optimized by evolution for effective killing
por: Michalska, Marta, et al.
Publicado: (2015)

Pseudomonas Exotoxin A Based Toxins Targeting Epidermal Growth Factor Receptor for the Treatment of Prostate Cancer
por: Fischer, Alexandra, et al.
Publicado: (2020)

Imaging of CAIX-expressing xenografts in vivo using (99m)Tc-HEHEHE-ZCAIX:1 Affibody molecule
por: HONARVAR, HADIS, et al.
Publicado: (2014)

Construction of an immunotoxin via site-specific conjugation of anti-Her2 IgG and engineered Pseudomonas exotoxin A
por: Lee, Byeong Sung, et al.
Publicado: (2019)

Cyclic versus Noncyclic Chelating Scaffold for (89)Zr-Labeled ZEGFR:2377 Affibody Bioconjugates Targeting Epidermal Growth Factor Receptor Overexpression
por: Summer, Dominik, et al.
Publicado: (2017)

Feasibility of Co-Targeting HER3 and EpCAM Using Seribantumab and DARPin–Toxin Fusion in a Pancreatic Cancer Xenograft Model
por: Xu, Tianqi, et al.
Publicado: (2023)

A pipeline to evaluate inhibitors of the Pseudomonas aeruginosa exotoxin U
por: Foulkes, Daniel M., et al.
Publicado: (2021)

The Use of a Non-Conventional Long-Lived Gallium Radioisotope (66)Ga Improves Imaging Contrast of EGFR Expression in Malignant Tumours Using DFO-ZEGFR:2377 Affibody Molecule
por: Oroujeni, Maryam, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_31m3tbr16k47vrncejui3tjr7n